The outcomes from clinical trials illustrate that FLT3 circumvention isn’t a useful strategy if used individually and that combinatorial therapeutic protocols of FLT3 inhibitors with other bioactive compounds affecting the apoptotic mechanisms could counteract drug mutation mechanisms and be clinically valuable for FLT3 harboring AML patients [18]. Here, FLT3 is linked to acute myeloid leukemia.